PT3891156T - Novas formas cristalinas de uma tienopirimidina como inibidor de mcl-1 - Google Patents

Novas formas cristalinas de uma tienopirimidina como inibidor de mcl-1

Info

Publication number
PT3891156T
PT3891156T PT198172298T PT19817229T PT3891156T PT 3891156 T PT3891156 T PT 3891156T PT 198172298 T PT198172298 T PT 198172298T PT 19817229 T PT19817229 T PT 19817229T PT 3891156 T PT3891156 T PT 3891156T
Authority
PT
Portugal
Prior art keywords
thienopyrimidine
mcl
inhibitor
crystalline forms
new crystalline
Prior art date
Application number
PT198172298T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of PT3891156T publication Critical patent/PT3891156T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT198172298T 2018-12-06 2019-12-05 Novas formas cristalinas de uma tienopirimidina como inibidor de mcl-1 PT3891156T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18306634 2018-12-06

Publications (1)

Publication Number Publication Date
PT3891156T true PT3891156T (pt) 2024-01-16

Family

ID=64665802

Family Applications (1)

Application Number Title Priority Date Filing Date
PT198172298T PT3891156T (pt) 2018-12-06 2019-12-05 Novas formas cristalinas de uma tienopirimidina como inibidor de mcl-1

Country Status (26)

Country Link
US (2) US12129261B2 (cg-RX-API-DMAC7.html)
EP (1) EP3891156B1 (cg-RX-API-DMAC7.html)
JP (1) JP7649241B2 (cg-RX-API-DMAC7.html)
KR (1) KR102855345B1 (cg-RX-API-DMAC7.html)
CN (1) CN113166169A (cg-RX-API-DMAC7.html)
AR (1) AR117255A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019391329B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021010072A2 (cg-RX-API-DMAC7.html)
CA (1) CA3121363A1 (cg-RX-API-DMAC7.html)
DK (1) DK3891156T3 (cg-RX-API-DMAC7.html)
EA (1) EA202191534A1 (cg-RX-API-DMAC7.html)
ES (1) ES2971258T3 (cg-RX-API-DMAC7.html)
FI (1) FI3891156T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240211T1 (cg-RX-API-DMAC7.html)
HU (1) HUE065266T2 (cg-RX-API-DMAC7.html)
IL (1) IL283656B2 (cg-RX-API-DMAC7.html)
LT (1) LT3891156T (cg-RX-API-DMAC7.html)
MA (1) MA54379B1 (cg-RX-API-DMAC7.html)
MD (1) MD3891156T2 (cg-RX-API-DMAC7.html)
MX (1) MX2021006702A (cg-RX-API-DMAC7.html)
PL (1) PL3891156T3 (cg-RX-API-DMAC7.html)
PT (1) PT3891156T (cg-RX-API-DMAC7.html)
RS (1) RS65047B1 (cg-RX-API-DMAC7.html)
SI (1) SI3891156T1 (cg-RX-API-DMAC7.html)
TW (1) TWI905090B (cg-RX-API-DMAC7.html)
WO (1) WO2020115183A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7900421B2 (ja) 2021-06-11 2026-08-04 ギリアード サイエンシーズ, インコーポレイテッド Mcl-1阻害剤と抗がん剤との組み合わせ
TWI861509B (zh) 2021-06-11 2024-11-11 美商基利科學股份有限公司 Mcl-1抑制劑與抗體藥物接合物之組合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008975A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
KR20210100148A (ko) 2021-08-13
IL283656B1 (en) 2025-06-01
TW202039511A (zh) 2020-11-01
AU2019391329A1 (en) 2021-07-01
MA54379A (fr) 2021-10-13
SI3891156T1 (sl) 2024-03-29
CN113166169A (zh) 2021-07-23
TWI905090B (zh) 2025-11-21
HUE065266T2 (hu) 2024-05-28
EA202191534A1 (ru) 2021-10-27
PL3891156T3 (pl) 2024-05-13
RS65047B1 (sr) 2024-02-29
JP2022511495A (ja) 2022-01-31
JP7649241B2 (ja) 2025-03-19
BR112021010072A2 (pt) 2021-08-24
WO2020115183A1 (en) 2020-06-11
LT3891156T (lt) 2023-12-27
ES2971258T3 (es) 2024-06-04
HRP20240211T1 (hr) 2024-04-26
AU2019391329B2 (en) 2024-09-26
AR117255A1 (es) 2021-07-21
IL283656B2 (en) 2025-10-01
EP3891156A1 (en) 2021-10-13
US20250011337A1 (en) 2025-01-09
MD3891156T2 (ro) 2024-06-30
DK3891156T3 (da) 2024-02-19
EP3891156B1 (en) 2023-11-15
NZ776907A (en) 2025-05-02
US12129261B2 (en) 2024-10-29
MA54379B1 (fr) 2023-12-29
CA3121363A1 (en) 2020-06-11
MX2021006702A (es) 2021-07-07
US20220017533A1 (en) 2022-01-20
IL283656A (en) 2021-07-29
FI3891156T3 (fi) 2024-02-07
KR102855345B1 (ko) 2025-09-03

Similar Documents

Publication Publication Date Title
IL292025B1 (en) Word flow annotation
IL287668A (en) Crystalline forms of a btk inhibitor
MA47596A (fr) Formes cristallines du dérivé 4-pyrimidinesulfamide aprocitentan
IL286218A (en) Solid state forms of ripretinib
DK3472157T3 (da) Krystallinske faste former af en bet-inhibitor
HUE064559T2 (hu) MAGL inhibitor kristályos formája
PL4393545T3 (pl) Nowe zastosowania pochodnych piperydynylo-indolowych
IL269792B (en) Crystalline forms of (s)-afoxolaner
EP3986902C0 (en) MACROCYCLIC MCL-1 INHIBITORS
IL279938A (en) Spirochromane derivatives
DK3580197T3 (da) Oprensning af pleuromutilin
IL282454A (en) Crystalline salts of a plasma kallikrein inhibitor
IL276853B2 (en) SGC-driven forms of aggression
DK3532057T3 (da) Prodrugs af kallikreininhibitorer
EP3831942A4 (en) INHIBITOR OF TDP-43 AGGREGATION
SI3749673T1 (sl) Kristalinična oblika biktegravir natrija
LT3749668T (lt) Nepertraukiamas trazodono gamybos būdas
PL3630725T3 (pl) Postać krystaliczna n-butylodeoksygalaktonojirymycyny
EP3866616A4 (en) PREPARATION OF CAROTINOID COMPOSITIONS
EP3793980A4 (en) CRYSTALLINE FORM OF S-APOMORPHINE
DK3891156T3 (da) Nye krystallinske former af et thienopyrimidin som mcl-1-inhibitor
IL286226A (en) Modulators of tdp-43
HUE062106T2 (hu) Peptid-epoxiketon-immunoproteaszóma inhibitor kristályos sói
PT3627206T (pt) Iluminação estruturada de uma amostra
IL281409A (en) Musk inhibition